(5Z)-7-{(1R,4S,5R,6R)-6-[(1E)-1-Octen-1-yl]-2,3-diazabicyclo[2.2.1]hept-2-en-5-yl}-5-heptenoic acid
Identification
- Generic Name
- (5Z)-7-{(1R,4S,5R,6R)-6-[(1E)-1-Octen-1-yl]-2,3-diazabicyclo[2.2.1]hept-2-en-5-yl}-5-heptenoic acid
- DrugBank Accession Number
- DB08675
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for (5Z)-7-{(1R,4S,5R,6R)-6-[(1E)-1-Octen-1-yl]-2,3-diazabicyclo[2.2.1]hept-2-en-5-yl}-5-heptenoic acid (DB08675)
- Weight
- Average: 332.4803
Monoisotopic: 332.246378278 - Chemical Formula
- C20H32N2O2
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UProstacyclin synthase Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as long-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- Sub Class
- Fatty acids and conjugates
- Direct Parent
- Long-chain fatty acids
- Alternative Parents
- Heterocyclic fatty acids / Amino fatty acids / Unsaturated fatty acids / Azo compounds / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organic oxides / Hydrocarbon derivatives show 1 more
- Substituents
- Aliphatic heteropolycyclic compound / Amino fatty acid / Azacycle / Azo compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Heterocyclic fatty acid / Hydrocarbon derivative / Long-chain fatty acid show 10 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- SRIZDZJPKIYUPZ-IDUFWMFESA-N
- InChI
- InChI=1S/C20H32N2O2/c1-2-3-4-5-6-9-12-16-17(19-15-18(16)21-22-19)13-10-7-8-11-14-20(23)24/h7,9-10,12,16-19H,2-6,8,11,13-15H2,1H3,(H,23,24)/b10-7-,12-9+/t16-,17-,18-,19+/m1/s1
- IUPAC Name
- (5Z)-7-[(1R,4S,5R,6R)-6-[(1E)-oct-1-en-1-yl]-2,3-diazabicyclo[2.2.1]hept-2-en-5-yl]hept-5-enoic acid
- SMILES
- [H]\C(CCCC(O)=O)=C(/[H])C[C@@]1([H])[C@]2([H])C[C@@]([H])(N=N2)[C@]1([H])C(\[H])=C(/[H])CCCCCC
References
- General References
- Not Available
- External Links
- PubChem Compound
- 94286438
- PubChem Substance
- 99445146
- ChemSpider
- 35034452
- ZINC
- ZINC000049872120
- PDBe Ligand
- U51
- PDB Entries
- 3b99
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000272 mg/mL ALOGPS logP 6.03 ALOGPS logP 5.07 Chemaxon logS -6.1 ALOGPS pKa (Strongest Acidic) 4.39 Chemaxon pKa (Strongest Basic) 1.13 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 62.02 Å2 Chemaxon Rotatable Bond Count 12 Chemaxon Refractivity 99.23 m3·mol-1 Chemaxon Polarizability 39.37 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9401 Caco-2 permeable - 0.5082 P-glycoprotein substrate Substrate 0.5 P-glycoprotein inhibitor I Non-inhibitor 0.7041 P-glycoprotein inhibitor II Non-inhibitor 0.9673 Renal organic cation transporter Non-inhibitor 0.7203 CYP450 2C9 substrate Non-substrate 0.8342 CYP450 2D6 substrate Non-substrate 0.7933 CYP450 3A4 substrate Non-substrate 0.5802 CYP450 1A2 substrate Non-inhibitor 0.7176 CYP450 2C9 inhibitor Non-inhibitor 0.7791 CYP450 2D6 inhibitor Non-inhibitor 0.9205 CYP450 2C19 inhibitor Non-inhibitor 0.8109 CYP450 3A4 inhibitor Non-inhibitor 0.9461 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9748 Ames test Non AMES toxic 0.7119 Carcinogenicity Non-carcinogens 0.8457 Biodegradation Not ready biodegradable 0.9393 Rat acute toxicity 2.3457 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8704 hERG inhibition (predictor II) Non-inhibitor 0.9674
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Prostaglandin-i synthase activity
- Specific Function
- Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).
- Gene Name
- PTGIS
- Uniprot ID
- Q16647
- Uniprot Name
- Prostacyclin synthase
- Molecular Weight
- 57103.385 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:33 / Updated at June 12, 2020 16:52